Stockscreener 앱 받기
53.35
5.31%
-2.99
전일 마감가:
$56.34
열려 있는:
$56.3
하루 거래량:
2.07M
Relative Volume:
1.19
시가총액:
$5.25B
수익:
$4.10M
순이익/손실:
$-568.53M
주가수익비율:
-8.5885
EPS:
-6.2118
순현금흐름:
$-401.18M
1주 성능:
-11.20%
1개월 성능:
+7.91%
6개월 성능:
-0.91%
1년 성능:
-9.58%
1일 변동 폭
$52.05
$56.65
1주일 범위
$52.05
$63.45
52주 변동 폭
$44.12
$78.48
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
53.35 | 5.25B | 4.10M | -568.53M | -401.18M | -6.2118 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-18 | 개시 | JP Morgan | Overweight |
| 2025-02-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-02-12 | 업그레이드 | TD Cowen | Sell → Hold |
| 2025-02-03 | 개시 | H.C. Wainwright | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-08-02 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | Guggenheim | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
CRISPR Therapeutics AG $CRSP Position Reduced by Sumitomo Mitsui Trust Group Inc. - MarketBeat
CRISPR Therapeutics AG (CRSP) stock dips while market gains: Key facts - MSN
CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts - Yahoo Finance
3 Reasons to Buy CRISPR Therapeutics Stock - The Motley Fool
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? - AOL.com
CRSP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $80 - GuruFocus
Vertex’s Crinetics Deal Balances Growth with Integration Risk - Investing.com
H.C. Wainwright reiterates CRISPR Therapeutics stock rating on label expansion By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates CRISPR Therapeutics stock rating on label expansion - Investing.com
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics - The Motley Fool
Bank of America Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
New CRISPR Technology Opens Opportunities in Biotech - Intellectia AI
CRISPR Therapeutics AG (CRSP) declines more than market: Some information for investors - MSN
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors - Yahoo Finance
Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now - The Motley Fool
CRSPCRISPR Therapeutics AG Options - Finviz
Citizens reiterates CRISPR Therapeutics stock rating on label expansion potential - Investing.com
Does CRISPR Therapeutics’ (CRSP) Russell Index Debut Quietly Reframe Its Biotech Growth Narrative? - Sahm
symbol__ Stock Quote Price and Forecast - CNN
CRISPR Therapeutics (CRSP) Price Forecast: Dual Breakout Targets Higher Prices - FXEmpire
CRISPR Therapeutics (CRSP) Is Up 11.3% After Broad Russell Growth Index Inclusion Has The Bull Case Changed? - Yahoo Finance
Crispr Therapeutics: Casgevy's Pediatric Win A Trigger For Bullish Sentiment - Seeking Alpha
CRSP News | CRISPR THERAPEUTICS AG (NASDAQ:CRSP) - ChartMill
CRSP Stock Pops As Morgan Stanley Doubles Price Target - timothysykes.com
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - Yahoo Finance
CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 2500 Growth Benchmark - marketscreener.com
ETFs Investing in CRISPR Therapeutics AG Stocks - TradingView
CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 2000 Growth Benchmark - marketscreener.com
CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 3000E Growth Benchmark - marketscreener.com
CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 3000 Growth Benchmark - marketscreener.com
Price to sales forward of CRISPR Therapeutics AG – NASDAQ:CRSP - TradingView
Price to sales forward of CRISPR Therapeutics AG – DUS:1CG - TradingView
Price to book forward of CRISPR Therapeutics AG – NASDAQ:CRSP - TradingView
Price to earnings forward of CRISPR Therapeutics AG – NASDAQ:CRSP - TradingView
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Price to book forward of CRISPR Therapeutics AG – DUS:1CG - TradingView
Enterprise value to revenue forward of CRISPR Therapeutics AG – NASDAQ:CRSP - TradingView
The Best Stocks to Invest $1,000 in Right Now - AOL.com
Enterprise value to revenue forward of CRISPR Therapeutics AG – DUS:1CG - TradingView
Enterprise value to EBITDA forward of CRISPR Therapeutics AG – NASDAQ:CRSP - TradingView
Enterprise value to EBIT forward of CRISPR Therapeutics AG – NASDAQ:CRSP - TradingView
CRISPR Therapeutics AG (CRSP) advances while market declines: Some information for investors - MSN
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Is CRISPR Therapeutics (CRSP) Finally Ready for Prime Time After Casgevy's Initial Success - Kavout | AI
Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade) (NASDAQ:BEAM) - Seeking Alpha
CRISPR Therapeutics AG Actuals & Estimates (NASDAQ:CRSP) - TradingView
CRSP Forecast — Price Target — Prediction for 2027 - TradingView
3 Companies Redefining Healthcare Innovation - Seeking Alpha
CRISPR Therapeutics AG (CRSP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):